AbbVie Is Maintained at Overweight by Morgan Stanley
Botox Innovator Revance Therapeutics Goes Private In Over $900M Deal
Correction to Big Drugmakers Are Clinching Smaller Deals Article -- WSJ
Express News | Abbvie Inc. : Morgan Stanley Raises Target Price to $218.00 From $211.00
Morgan Stanley Adjusts Price Target on AbbVie to $218 From $211, Maintains Overweight Rating
The Yen Carry Trade Is a Distraction. Stocks Have More Fundamental Problems, Says Morgan Stanley's Wilson
Robert Bruce Amplifies Stake in AbbVie Inc, Highlighting Strategic Portfolio Adjustments in Q2 2024
Healthcare Stocks Are Closing the Gap. Here Are the Latest Winners.
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
AbbVie Inc. (ABBV): Among the Best Cosmetic Surgery and Aesthetics Stocks To Buy Now
Aldeyra Climbs After Late-stage Success for Dry Eye Disease Therapy
Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight
AbbVie | 10-Q: Q2 2024 Earnings Report
Insider Sale: Executive Chairman Richard Gonzalez Sells 66,500 Shares of AbbVie Inc (ABBV)
Warren Buffett's Approach To Investing In Election Years
AbbVie Inc. (ABBV) Elliott Wave Technical Analysis [Video]
Top Overweight and Low-volatility Picks in Staples, Healthcare, and Utilities - WF
AbbVie, Leidos, KKR And More On CNBC's 'Final Trades'
Express News | Cantor Fitzgerald Reiterates Overweight on AbbVie, Maintains $200 Price Target
AbbVie Analyst Ratings